Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone ...

Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new ...

Global markets have recently shown mixed performances, with the S&P 500 and Nasdaq Composite both closing out a strong year despite some volatility and profit-taking towards year-end. In this ...

Chinese biotech Innovent Biologics (OTCPK:IVBIY) (OTCPK:IVBXF) has entered into a collaboration and licensing agreement with ...

Innovent Biologics and Roche have entered a partnership and exclusive licence agreement to accelerate the development of a ...

In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality ...

Analyst Jill Wu of CMB International Securities maintained a Buy rating on Innovent Biologics (IVBXF – Research Report), boosting the price ...

Innovent inks exclusive global license agreement with Roche to advance the development of IBI3009, a novel DLL3 targeted ADC candidate: San Francisco, US Friday, January 3, 2025, ...

Innovent Biologics (HK:1801) has released an update.Don't Miss Our New Year's Offers:Discover the latest stocks recommended by top Wall Street ...

Mumbai, India-based Mankind Pharma has entered into a partnership with China’s Innovent Biologics for exclusively licensing ...

ET Net News Agency, 8 January 2025] A direct manual trade of 1.67 million shares of INNOVENT BIO (01801) was registered at 1:00p.m. The deal amounted to HK$56.6m, or at HK$33.8 p ...